Visible Genetics targets disease diagnostics
This article was originally published in Clinica
Visible Genetics is nearing completion of trials of its p53 GeneKit for breast cancer and expects to publish results within "several months". The Canadian company has developed three gene- specific test kits using stratified matrix testing methods to identify disease-associated mutations. The kits are designed to run on the company's DNA sequencer, the OpenGene system, which is based on ultra-thin electrophoretic gel cassette technology.
You may also be interested in...
Policy experts predicted how the incoming Biden administration will handle health care issues at a recent Alliance for Health Policy webinar. Rachel Nuzum, VP of state and federal policy at The Commonwealth Fund, said telehealth could be a priority.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.